DDInter624 DDInter481
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Voriconazole
Voriconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Cytochrome P450 2C9 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Voriconazole
Voriconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Efavirenz {u} (Compound) causes {v} (Side Effect) Arthralgia
Arthralgia {u} (Side Effect) is caused by {v} (Compound) Voriconazole
Voriconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Oritavancin
Oritavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Efavirenz {u} (Compound) causes {v} (Side Effect) Enlargement abdomen
Enlargement abdomen {u} (Side Effect) is caused by {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Darolutamide
Efavirenz {u} (Compound) causes {v} (Side Effect) Glycosuria
Glycosuria {u} (Side Effect) is caused by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Darolutamide
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Delavirdine
Delavirdine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Voriconazole (Compound) and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Efavirenz (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) includes Voriconazole (Compound) and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Efavirenz (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Voriconazole (Compound) and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Oritavancin (Compound) and Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Efavirenz (Compound) causes Enlargement abdomen (Side Effect) and Enlargement abdomen (Side Effect) is caused by Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide
Efavirenz (Compound) causes Glycosuria (Side Effect) and Glycosuria (Side Effect) is caused by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Delavirdine (Compound) and Delavirdine may cause a minor interaction that can limit clinical effects when taken with Darolutamide